Logotype for Immix Biopharma Inc

Immix Biopharma (IMMX) investor relations material

Immix Biopharma Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immix Biopharma Inc
Q2 2025 earnings summary8 Aug, 2025

Executive summary

  • Focused on CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, with ongoing Phase 1b/2 trials in the US and ex-US, and expansion to 18 clinical sites as of July 2025.

  • NXC-201 has received FDA RMAT and Orphan Drug Designation, as well as European ODD, and has shown high response rates in clinical data presented at major conferences.

  • Awarded an $8M CIRM grant to support NXC-201 clinical development, with $3.6M received and $4.4M remaining as of August 2025.

  • Company operates as a single segment, with all significant decisions made at the consolidated level.

Financial highlights

  • Cash and cash equivalents were $11.6M as of June 30, 2025, with $12M reported in a subsequent update.

  • Net loss for Q2 2025 was $6.6M, up from $4.4M in Q2 2024; net loss for the six months ended June 30, 2025 was $11.2M, up from $9.7M year-over-year.

  • General and administrative expenses for Q2 2025 were $2.7M (up from $2.5M), and R&D expenses were $4.0M (up from $2.2M) compared to Q2 2024.

  • Interest income declined to $104K in Q2 2025 from $307K in Q2 2024 due to lower cash balances.

  • Net cash used in operating activities for the six months ended June 30, 2025 was $7.0M, down from $9.1M in the prior year period.

Outlook and guidance

  • Management expects continued operating losses and insufficient capital to fund operations for the next twelve months, indicating substantial doubt about the ability to continue as a going concern.

  • Plans to seek additional capital through equity, debt, grants, or strategic partnerships; alternatives to the current business plan may be considered if funding is not secured.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Immix Biopharma earnings date

Logotype for Immix Biopharma Inc
Q3 202510 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Immix Biopharma earnings date

Logotype for Immix Biopharma Inc
Q3 202510 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Immix Biopharma Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases. The company’s lead programs are based on its proprietary tissue-specific therapeutics platform, designed to deliver biologics and small molecules to specific tissues while minimizing systemic toxicity. Immix Biopharma conducts clinical trials for rare and hard-to-treat cancers, as well as immune-related conditions. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage